Upal Basu Roy: How immune cells can be engineered to target EGFR+ NSCLC

Upal Basu Roy, Executive Director of Research at LUNGevity Foundation, shared about a Facebook Live event hosted by LUNGevity Foundation. Read his post on LinkedIn below:

“Are you interested in learning about EGFR-positive non-small cell lung cancer?

Please join me for a Facebook Live event hosted by LUNGevity Foundation that explores how immune cells can be engineered to target EGFR+ NSCLC.

• Date: Thursday, October 10
• Time: 12 PM Eastern Time
• Where: Tune in here

Joining me will be Jill Feldman and Laura Book from the EGFR Resisters, along with Alexandre Reuben, PhD from the MD Anderson Cancer Center. Dr. Reuben received a 2023 EGFR Resisters/LUNGevity Foundation grant.

I hope to see you there!”